Biontech/Pfizer: third booster vaccination?
To improve the Biontech/Pfizer coronavirus vaccine and against the new mutations, the pharmaceutical project has already brought a third possible vaccination into play. Scientific studies are currently still being awaited. However, a third booster is considered likely.
Pfizer and Biontech have conducted studies investigatesaccording to which a third dose of the vaccine six months after the second vaccination could result in a high neutralizing antibody formation against the new mutations. This would also have a "consistent tolerability profile". Antibody formation is said to be around five to ten times higher.
According to the data from the isral vaccination company, the effect of the vaccine decreases after just six months following the second vaccination. A third vaccination would provide greater protection and additional protection against the delta variant B.1.617.2.
New vaccine to protect against delta variant
Pfizer/Biontech is already developing a new mRNA vaccine version in which the complete spike protein of the delta variant is used. Vaccine protection against severe courses would remain high after the second dose. However, a decline in efficacy against symptomatic courses cannot be ruled out. In addition, further virus mutations can be expected over time, as Pfizer and Biontech write.
Pfizer and Biontech plan to submit the data obtained to the FDA, EMA and other regulatory authorities in the coming weeks. Further current preclinical and clinical studies are currently being conducted to confirm the hypotheses.
Sources: Heise/biontech.de
